Literature DB >> 31423211

Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection.

Reiichiro Kondo1, Jun Akiba2, Sachiko Ogasawara1, Osamu Nakashima3, Yoshiki Naito2, Hironori Kusano1, Yutaro Mihara1, Masahiko Tanigawa1, Hirohisa Yano1.   

Abstract

The aim of the present study was to study the pathological prognostic factor of initial hepatocellular carcinoma (HCC) after archiving sustained virologic response (SVR) for hepatitis C virus (HCV) infection. A single-center retrospective analysis was performed for patients who underwent hepatectomy between 2003 and 2017. We studied clinico-pathological findings of resected liver tissues in 35 patients with HCC after SVR treated by interferon (IFN group) and 13 patients with HCC after SVR treated by direct acting antivirals (DAA group). We also performed immunohistochemical staining using antibodies against programmed death-ligand 1 (PD-L1), cytokeratin 19, epithelial cell adhesion molecule (EpCAM) and regulator of G-protein signaling 5 (RGS5). PD-L1 positive HCC was observed in 6 cases of the IFN group and 4 cases of the DAA group. In the IFN group, in univariate analysis of recurrence free survival after surgery (RFS), the PD-L1 expression had a statistically significant impact (HR=6.01; P=0.02). In the multivariate analysis of RFS, PD-L1 expression significantly remained (HR=5.01; P=0.03). For both RFS and overall survival, Kaplan-Meier curves confirmed that patients with PD-L1 expression showed significantly worse prognosis (log-rank test P<0.01). Nuclear grade, RGS5 expression, and EpCAM expression were significantly higher in the PD-L1-positive HCC group compared with the PD-L1-negative HCC group (P<0.05). Therefore, PD-L1 expression may be an independent prognostic factor of surgically resected HCC after achieving SVR.

Entities:  

Keywords:  biomarker; hepatocellular carcinoma; pathology; programmed death-ligand 1; sustained virologic response

Year:  2019        PMID: 31423211      PMCID: PMC6607026          DOI: 10.3892/ol.2019.10448

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Authors:  Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Kentaro Yoshioka; Hirohito Tsubouchi; Kendo Kiyosawa; Shinichi Kakumu; Kiwamu Okita; Norio Hayashi; Takeshi Okanoue
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

2.  The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis.

Authors:  A Martinez-Hernandez; J Martinez
Journal:  Hepatology       Date:  1991-11       Impact factor: 17.425

3.  Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.

Authors:  Yasuji Arase; Mariko Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Yusuke Kawamura; Norio Akuta; Masahiro Kobayashi; Hitomi Sezaki; Satoshi Saito; Tetsuya Hosaka; Kenji Ikeda; Hiromitsu Kumada; Tetsuro Kobayashi
Journal:  Hepatology       Date:  2013-02-07       Impact factor: 17.425

4.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

5.  Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Authors:  Qiang Gao; Xiao-Ying Wang; Shuang-Jian Qiu; Ichiro Yamato; Masayuki Sho; Yoshiyuki Nakajima; Jian Zhou; Bai-Zhou Li; Ying-Hong Shi; Yong-Sheng Xiao; Yang Xu; Jia Fan
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

6.  Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Authors:  Miharu Hirakawa; Kenji Ikeda; Yasuji Arase; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Masahiro Kobayashi; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Hiromitsu Kumada
Journal:  Intern Med       Date:  2008-10-01       Impact factor: 1.271

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection.

Authors:  Takehiro Hayashi; Akihiro Tamori; Manabu Nishikawa; Hiroyasu Morikawa; Masaru Enomoto; Hiroki Sakaguchi; Daiki Habu; Norifumi Kawada; Shoji Kubo; Shuhei Nishiguchi; Susumu Shiomi
Journal:  Liver Int       Date:  2008-05-19       Impact factor: 5.828

Review 9.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

10.  Development of murine hepatic sinusoidal endothelial cells characterized by the expression of hyaluronan receptors.

Authors:  Hidenori Nonaka; Minoru Tanaka; Kaori Suzuki; Atsushi Miyajima
Journal:  Dev Dyn       Date:  2007-08       Impact factor: 3.780

View more
  1 in total

1.  Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.

Authors:  Guosheng Yuan; Yangda Song; Qi Li; Xiaoyun Hu; Mengya Zang; Wencong Dai; Xiao Cheng; Wei Huang; Wenxuan Yu; Mian Chen; Yabing Guo; Qifan Zhang; Jinzhang Chen
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.